Joseph Clark is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2160 S First Ave
Luh-North Ent., Rm. 7604
Maywood, IL 60153
Telephone
708-216-3304Provider last certified this registry record 28 Jan 2022.
Clinical trials
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Sponsor: Beth Israel Deaconess Medical Center
- S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Sponsor: SWOG Cancer Research Network
- Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Sponsor: Loyola University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20224 payments
- E.R. Squibb & Sons, L.L.C.Program year20223 payments
- E.R. Squibb & Sons, L.L.C.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.4%Kinase inhibitor28.4%Cabometyx51%Inlyta25%Sorafenib8%Mekinist6%Tafinlar5%Vitrakvi5%Part D<11 patientsHormonal (systemic)
23.2%l-Thyroxine23.2%Levothyroxine Sodium100%Part D≥52 patientsMetabolism & gastrointestinal
21%Corticosteroid7.9%Prednisone100%Part D≥26 patientsSerotonin-3 Receptor Antagonist3.9%Ondansetron Hcl100%Part D≥11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2016–2017 per NIH RePORTER. The latest:
- A General Intermolecular Benzylic C-H Amination Employing an Earth Abundant Metal
University of Illinois at Urbana-Champaign
FY2017$750F32GM112501 - A General Intermolecular Benzylic C-H Amination Employing an Earth Abundant Metal
University of Illinois at Urbana-Champaign
FY2016$56,118F32GM112501
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”